327 related articles for article (PubMed ID: 17899308)
21. Parotid irrigation and cevimeline gargle for treatment of xerostomia in Sjögren's syndrome.
Takagi Y; Katayama I; Tashiro S; Nakamura T
J Rheumatol; 2008 Nov; 35(11):2289-91. PubMed ID: 19004065
[No Abstract] [Full Text] [Related]
22. Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations.
von Bültzingslöwen I; Sollecito TP; Fox PC; Daniels T; Jonsson R; Lockhart PB; Wray D; Brennan MT; Carrozzo M; Gandera B; Fujibayashi T; Navazesh M; Rhodus NL; Schiødt M
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S57.e1-15. PubMed ID: 17379156
[TBL] [Abstract][Full Text] [Related]
23. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 3rd communication: effects on respiratory and cardiovascular systems.
Arisawa H; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(3):162-7. PubMed ID: 11963642
[TBL] [Abstract][Full Text] [Related]
24. Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management.
Al-Hashimi I
Drugs Aging; 2005; 22(11):887-99. PubMed ID: 16323968
[TBL] [Abstract][Full Text] [Related]
25. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects.
Arisawa H; Fukui K; Imai E; Fujise N; Masunaga H
Arzneimittelforschung; 2002; 52(4):225-32. PubMed ID: 12040964
[TBL] [Abstract][Full Text] [Related]
26. The therapy of Sjogren's syndrome: a review.
Coaccioli S; Giuliani M; Puxeddu A
Clin Ter; 2007; 158(5):453-6. PubMed ID: 18062353
[TBL] [Abstract][Full Text] [Related]
27. Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sjögren syndrome: a double-blind randomized controlled trial.
Cifuentes M; Del Barrio-Díaz P; Vera-Kellet C
Br J Dermatol; 2018 Nov; 179(5):1056-1061. PubMed ID: 29432648
[TBL] [Abstract][Full Text] [Related]
28. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle.
Arisawa H; Fukui K; Fujise N; Masunaga H
Arzneimittelforschung; 2002; 52(2):81-8. PubMed ID: 11878203
[TBL] [Abstract][Full Text] [Related]
29. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
Khurshudian AV
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of oral dryness in Sjögren's syndrome].
Mariette X
Rev Med Interne; 2004 Apr; 25(4):287-93. PubMed ID: 15112663
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis on pharmacological therapies in the management of xerostomia in patients with Sjogren's syndrome.
Garlapati K; Kammari A; Badam RK; B E S; Boringi M; Soni P
Immunopharmacol Immunotoxicol; 2019 Apr; 41(2):312-318. PubMed ID: 30932714
[No Abstract] [Full Text] [Related]
32. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
[TBL] [Abstract][Full Text] [Related]
33. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome.
Fox RI
Adv Exp Med Biol; 2002; 506(Pt B):1107-16. PubMed ID: 12614037
[No Abstract] [Full Text] [Related]
34. Effect of a muscarinic M3 receptor agonist on gastric motility.
Chiba T; Kudara N; Sato M; Inomata M; Orii S; Suzuki K
J Gastroenterol Hepatol; 2007 Nov; 22(11):2039-41. PubMed ID: 17914991
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study.
Brimhall J; Jhaveri MA; Yepes JF
Spec Care Dentist; 2013; 33(3):123-7. PubMed ID: 23600983
[TBL] [Abstract][Full Text] [Related]
36. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation.
Omori Y; Asari T; Maruyama K; Kusama H; Kojima M; Shibata N
Arzneimittelforschung; 2003; 53(5):342-50. PubMed ID: 12854361
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjögren's syndrome.
Tomiita M; Takei S; Kuwada N; Nonaka Y; Saito K; Shimojo N; Kohno Y
Mod Rheumatol; 2010 Oct; 20(5):486-90. PubMed ID: 20517630
[TBL] [Abstract][Full Text] [Related]
38. Effects of cevimeline on the immunolocalization of aquaporin-5 and the ultrastructure of salivary glands in Sjögren's syndrome model mice.
Nishimura H; Yakeishi A; Saga T; Yamaki K
Kurume Med J; 2009; 56(3-4):39-47. PubMed ID: 20505281
[TBL] [Abstract][Full Text] [Related]
39. The use of oral pilocarpine in xerostomia and Sjögren's syndrome.
Nusair S; Rubinow A
Semin Arthritis Rheum; 1999 Jun; 28(6):360-7. PubMed ID: 10406404
[TBL] [Abstract][Full Text] [Related]
40. Pilocarpine treatment in a mixed cohort of xerostomic patients.
Aframian DJ; Helcer M; Livni D; Robinson SD; Markitziu A; Nadler C
Oral Dis; 2007 Jan; 13(1):88-92. PubMed ID: 17241436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]